Advertiser Disclosure: We may earn commissions from partner links at no cost to you. This never affects our editorial content or recommendations.

Healthcare AI NYSE: VEEV

Veeva Systems Inc. (VEEV)

The cloud operating system for life sciences — running R&D, clinical trials, and commercial operations at every major pharma.

— loading… 15-min delay · Not financial advice
✓ Reviewed by Get AI Decoded Editorial Team Updated April 2026
← All Healthcare AI Stocks

Sponsored Placement Available

Sponsor this VEEV page — reach investors tracking VEEV

View Options →

The AI Angle

Veeva Systems builds the industry-specific cloud software that pharmaceutical and biotech companies use to run their operations — from CRM and regulatory submissions to clinical data management and quality control. Unlike horizontal SaaS (Salesforce, Workday), Veeva built vertically: every feature, every workflow, and every compliance module is designed for life sciences. This creates extraordinary switching costs: ripping out Veeva from a top-20 pharma's clinical operation is a multi-year, tens-of-millions-dollar project.

Veeva's AI strategy is to embed AI capabilities natively into its existing workflows — Veeva Vault AI for clinical data extraction, Veeva CRM Bot for sales force automation, and Vault Clinical Ops AI for site monitoring. The GLP-1 drug boom is a direct tailwind: Lilly, Novo Nordisk, Roche, and Pfizer are all Veeva customers expanding usage as they scale new drug franchises. Fiscal year 2026 (ending January 2026) revenue reached $3.2 billion, with the company having achieved its $3 billion run rate milestone. Q1 FY2027 revenue is guided to approximately $856.5 million.

Key Numbers

$3.2B
FY2026 Full Year Revenue
Fiscal year ending Jan 31, 2026; PRNewswire Mar 4, 2026
$836M
Q4 FY2026 Revenue
+16% YoY (Veeva IR, Mar 4, 2026)
~$856.5M midpoint
Q1 FY2027 Revenue Guidance
Above analyst estimates (IndexBox, Mar 2026)
3/5
AI Exposure Score
Significant AI exposure.
⚡⚡⚡⚡⚡
⚡ About AI Exposure Score: Reflects how central AI is to this company's current revenue and growth strategy. 5 = AI is the core business. 1 = AI is a minor angle. Editorial assessment — not a buy/sell signal.

Get VEEV coverage in your inbox

We cover VEEV and 24 other AI stocks every morning. Free daily newsletter.

Upcoming Catalysts

  • Vault Platform expansion: CRM, CDMS, RIM, QMS all migrating to Vault from legacy
  • AI-native features (Vault AI, CRM Bot) driving upsell at existing accounts
  • GLP-1 drug buildout: Lilly, Novo, and new obesity drug entrants expanding Veeva usage
  • International expansion: Veeva underpenetrated in China, Japan, and EM pharma

Key Risks

  • Veeva is fully committed to Salesforce platform exit by Sept 2025 — migration execution risk
  • Revenue growth moderating from 20%+ to mid-teens as large accounts fully deployed
  • Competition from Oracle Health Sciences, IQVIA, and niche clinical cloud players
  • Life sciences R&D budget cuts (Lilly, Pfizer) could slow expansion spending

Sources: Veeva IR (Mar 4, 2026), PRNewswire (Mar 4, 2026), IndexBox (Mar 2026)

⚠️ Not financial advice. This page is for informational purposes only. All figures are sourced from public earnings reports, company guidance, and financial news. Past performance is not indicative of future results. Always do your own research before making any investment decisions.

Trade VEEV with a top broker

Open a brokerage account to start trading. We may earn a commission if you use these links — see our disclosure.

R
Robinhood
Commission-free. No minimums.
Open Account →
T
Tastytrade
Built for active traders & options.
Open Account →
W
Webull
Advanced charts. Extended hours.
Open Account →